Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Pediatric Nephrology
Erschienen in: Pediatric Nephrology 7/2006

01.07.2006 | Conference Report

Assessment and treatment of short stature in pediatric patients with chronic kidney disease: a consensus statement

verfasst von: John D. Mahan, Bradley A. Warady, Consensus Committee

Erschienen in: Pediatric Nephrology | Ausgabe 7/2006

Einloggen, um Zugang zu erhalten

Abstract

Growth failure is a clinically important issue in children with chronic kidney disease (CKD) and is associated with significant morbidity and mortality. Many factors contribute to impaired growth in these children, including abnormalities in the growth hormone (GH)–insulin-like growth factor-I (IGF-I) axis, malnutrition, acidosis, and renal bone disease. The management of growth failure in children with CKD is complicated by the presence of other disease-related complications requiring medical intervention. Despite evidence of GH efficacy and safety in this population, some practitioners and families have been reluctant to institute GH therapy, citing an unwillingness to comply with daily injections, reimbursement difficulties, or impending renal transplantation. Suboptimal attention to growth failure management may be further compounded by a lack of clinical guidelines for the appropriate assessment and treatment of growth failure in these children. This review of growth failure in children with CKD concludes with an algorithm developed by members of the consensus committee, outlining their recommendations for appropriate steps to improve growth and overall health outcomes in children with CKD.
Literatur
1.
Furth SL, Stablein D, Fine RN, Powe NR, Fivush BA (2002) Adverse clinical outcomes associated with short stature at dialysis initiation: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatrics 109:909–913PubMedCrossRef
2.
Furth SL, Hwang W, Yang C, Neu AM, Fivush BA, Powe NR (2002) Growth failure, risk of hospitalization and death for children with end-stage renal disease. Pediatr Nephrol 17:450–455PubMedCrossRef
3.
Hokken-Koelega AC, Saenger P, Cappa M, Greggio N (2001) Unresolved problems concerning optimal therapy of puberty in children with chronic renal diseases. J Pediatr Endocrinol Metab 14 [Suppl 2]:945–952PubMed
4.
Kari JA, Gonzalez C, Ledermann SE, Shaw V, Rees L (2000) Outcome and growth of infants with severe chronic renal failure. Kidney Int 57:1681–1687PubMedCrossRef
5.
Kuizon BD, Salusky IB (1999) Growth retardation in children with chronic renal failure. J Bone Miner Res 14:1680–1690CrossRefPubMed
6.
Postlethwaite RJ, Eminson DM, Reynolds JM, Wood AJ, Hollis S (1998) Growth in renal failure: a longitudinal study of emotional and behavioural changes during trials of growth hormone treatment. Arch Dis Child 78:222–229PubMedPubMedCentralCrossRef
7.
Scharer K (1990) Growth and development of children with chronic renal failure. Study Group on Pubertal Development in Chronic Renal Failure. Acta Paediatr Scand Suppl 366:90–92PubMedCrossRef
8.
Tonshoff B, Mehls O (1995) Growth retardation in children with chronic renal insufficiency: current aspects of pathophysiology and treatment. J Nephrol 8:133–142
9.
National Kidney Foundation Kidney Disease Outcomes Quality Initiative (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Part 4. Definition and classification of stages of chronic kidney disease. National Kidney Foundation. Accessed 13 Sept 2004
10.
11.
Tonshoff B, Fine RN (1996) Recombinant human growth hormone for children with renal failure. Adv Ren Replace Ther 3:37–47CrossRefPubMed
12.
Stabler B, Siegel PT, Tancer ME (1993) Psychiatric symptoms in young adults treated for growth hormone deficiency in childhood. In: Stabler B, Underwood L (eds) Growth, stature, and adaptation. Behavioral, social and cognitive aspects of growth delay. University of North Carolina, Chapel Hill, NC, pp 99–106
13.
Stabler B, Siegel PT, Clopper RR, Stoppani CE, Compton PG, Underwood LE (1998) Behavior change after growth hormone treatment of children with short stature. J Pediatr 133:366–373PubMedCrossRef
14.
Stabler B, Clopper RR, Siegel PT, Stoppani C, Compton PG, Underwood LE (1994) Academic achievement and psychological adjustment in short children. The National Cooperative Growth Study. J Dev Behav Pediatr 15:1–6PubMedCrossRef
15.
Hokken-Koelega AC, van Zaal MA, van Bergen W, de Ridder MA, Stijnen T, Wolff ED, de Jong RC, Donckerwolcke RA, de Muinck Keizer-Schrama SM, Drop SL (1994) Final height and its predictive factors after renal transplantation in childhood. Pediatr Res 36:323–328PubMedCrossRef
16.
Fine RN, Stablein D (2005) Long-term use of recombinant human growth hormone in pediatric allograft recipients: a report of the NAPRTCS Transplant Registry. Pediatr Nephrol 20:404–408CrossRefPubMed
17.
Nissel R, Brazda I, Feneberg R, Wigger M, Greiner C, Querfeld U, Haffner D (2004) Effect of renal transplantation in childhood on longitudinal growth and adult height. Kidney Int 66:792–800PubMedCrossRef
18.
Voss LD, Sandberg DE (2004) The psychological burden of short stature: evidence against. Eur J Endocrinol 151 [Suppl 1]:S29–S33PubMedCrossRef
19.
Busschbach JJ, Rikken B, Grobbee DE, De Charro FT, Wit JM (1998) Quality of life in short adults. Horm Res 49:32–38PubMedCrossRef
20.
Broyer M, Le BC, Charbit M, Guest G, Tete MJ, Gangnadoux MF, Niaudet P (2004) Long-term social outcome of children after kidney transplantation. Transplantation 77:1033–1037PubMedCrossRef
21.
Rosenkranz J, Reichwald-Klugger E, Oh J, Turzer M, Mehls O, Schaefer F (2005) Psychosocial rehabilitation and satisfaction with life in adults with childhood-onset of end-stage renal disease. Pediatr Nephrol 20:1288–1294PubMedCrossRef
22.
Roelfsema V, Clark RG (2001) The growth hormone and insulin-like growth factor axis: its manipulation for the benefit of growth disorders in renal failure. J Am Soc Nephrol 12:1297–1306PubMed
23.
Rabkin R, Sun DF, Chen Y, Tan J, Schaefer F (2005) Growth hormone resistance in uremia, a role for impaired JAK/STAT signaling. Pediatr Nephrol 20:313–318CrossRefPubMed
24.
Tonshoff B, Kiepe D, Ciarmatori S (2005) Growth hormone/insulin-like growth factor system in children with chronic renal failure. Pediatr Nephrol 20:279–289PubMedCrossRef
25.
Schaefer F, Veldhuis JD, Robertson WR, Dunger D, Scharer K (1994) Immunoreactive and bioactive luteinizing hormone in pubertal patients with chronic renal failure. Cooperative Study Group on Pubertal Development in Chronic Renal Failure. Kidney Int 45:1465–1476PubMedCrossRef
26.
27.
28.
29.
30.
Karlberg J, Schaefer F, Hennicke M, Wingen AM, Rigden S, Mehls O (1996) Early age-dependent growth impairment in chronic renal failure. European Study Group for Nutritional Treatment of Chronic Renal Failure in Childhood. Pediatr Nephrol 10:283–287PubMedCrossRef
31.
Uauy RD, Hogg RJ, Brewer ED, Reisch JS, Cunningham C, Holliday MA (1994) Dietary protein and growth in infants with chronic renal insufficiency: a report from the Southwest Pediatric Nephrology Study Group and the University of California, San Francisco. Pediatr Nephrol 8:45–50PubMedCrossRef
32.
Parekh RS, Flynn JT, Smoyer WE, Milne JL, Kershaw DB, Bunchman TE, Sedman AB (2001) Improved growth in young children with severe chronic renal insufficiency who use specified nutritional therapy. J Am Soc Nephrol 12:2418–2426PubMed
33.
Wingen AM, Mehls O (2002) Nutrition in children with preterminal chronic renal failure. Myth or important therapeutic aid? Pediatr Nephrol 17:111–120PubMedCrossRef
34.
Caldas A, Broyer M, Dechaux M, Kleinknecht C (1992) Primary distal tubular acidosis in childhood: clinical study and long-term follow-up of 28 patients. J Pediatr 121:233–241PubMedCrossRef
35.
Maniar S, Kleinknecht C, Zhou X, Motel V, Yvert JP, Dechaux M (1996) Growth hormone action is blunted by acidosis in experimental uremia or acid load. Clin Nephrol 46:72–76PubMed
36.
Bushinsky DA, Frick KK (2000) The effects of acid on bone. Curr Opin Nephrol Hypertens 9:369–379PubMedCrossRef
37.
Lim VS, Kopple JD (2000) Protein metabolism in patients with chronic renal failure: role of uremia and dialysis. Kidney Int 58:1–10PubMedCrossRef
38.
Boirie Y, Broyer M, Gagnadoux MF, Niaudet P, Bresson JL (2000) Alterations of protein metabolism by metabolic acidosis in children with chronic renal failure. Kidney Int 58:236–241PubMedCrossRef
39.
Kuizon BD, Goodman WG, Juppner H, Boechat I, Nelson P, Gales B, Salusky IB (1998) Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD. Kidney Int 53:205–211PubMedCrossRef
40.
Hochberg Z (2002) Mechanisms of steroid impairment of growth. Horm Res 58 [Suppl 1]:33–38PubMed
41.
National Kidney Foundation Kidney Disease Outcomes Quality Initiative (2000) Clinical practice guidelines for nutrition in chronic renal failure. National Kidney Foundation. Accessed 15 Jan 2004
42.
Kaufman DB (1998) Growth hormone and renal osteodystrophy: a case report. Pediatr Nephrol 12:157–159CrossRefPubMed
43.
Fine RN, Kohaut EC, Brown D, Perlman AJ (1994) Growth after recombinant human growth hormone treatment in children with chronic renal failure: report of a multicenter randomized double-blind placebo-controlled study. Genentech Cooperative Study Group. J Pediatr 124:374–382CrossRefPubMed
44.
Hokken-Koelega A, Mulder P, De Jong R, Lilien M, Donckerwolcke R, Groothof J (2000) Long-term effects of growth hormone treatment on growth and puberty in patients with chronic renal insufficiency. Pediatr Nephrol 14:701–706PubMedCrossRef
45.
Kari JA, Rees L (2005) Growth hormone for children with chronic renal failure and on dialysis. Pediatr Nephrol 20:618–621CrossRefPubMed
46.
Haffner D, Schaefer F, Nissel R, Wuhl E, Tonshoff B, Mehls O (2000) Effect of growth hormone treatment on the adult height of children with chronic renal failure. German Study Group for Growth Hormone Treatment in Chronic Renal Failure. N Engl J Med 343:923–930CrossRefPubMed
47.
Hokken-Koelega AC, Stijnen T, de Ridder MA, de Muinck Keizer-Schrama SM, Wolff ED, de Jong MC, Donckerwolcke RA, Groothoff JW, Blum WF, Drop SL (1994) Growth hormone treatment in growth-retarded adolescents after renal transplant. Lancet 343:1313–1317PubMedCrossRef
48.
Berard E, Crosnier H, Six-Beneton A, Chevallier T, Cochat P, Broyer M (1998) Recombinant human growth hormone treatment of children on hemodialysis. French Society of Pediatric Nephrology. Pediatr Nephrol 12:304–310PubMedCrossRef
49.
Jabs K, Van DC, Harmon WE (1993) Growth hormone treatment of growth failure among children with renal transplants. Kidney Int Suppl 43:S71–S75PubMed
50.
Guest G, Berard E, Crosnier H, Chevallier T, Rappaport R, Broyer M (1998) Effects of growth hormone in short children after renal transplantation. French Society of Pediatric Nephrology. Pediatr Nephrol 12:437–446CrossRefPubMed
51.
Fine RN, Stablein D, Cohen AH, Tejani A, Kohaut E (2002) Recombinant human growth hormone post-renal transplantation in children: a randomized controlled study of the NAPRTCS. Kidney Int 62:688–696CrossRefPubMed
52.
Vimalachandra D, Craig JC, Cowell CT, Knight JF (2001) Growth hormone treatment in children with chronic renal failure: a meta-analysis of randomized controlled trials. J Pediatr 139:560–567PubMedCrossRef
53.
Maxwell H, Rees L (1998) Randomised controlled trial of recombinant human growth hormone in prepubertal and pubertal renal transplant recipients. British Association for Pediatric Nephrology. Arch Dis Child 79:481–487PubMedPubMedCentralCrossRef
54.
Powell DR, Liu F, Baker BK, Hintz RL, Lee PD, Durham SK, Brewer ED, Frane JW, Watkins SL, Hogg RJ (1997) Modulation of growth factors by growth hormone in children with chronic renal failure. The Southwest Pediatric Nephrology Study Group. Kidney Int 51:1970–1979PubMedCrossRef
55.
Wuhl E, Haffner D, Nissel R, Schaefer F, Mehls O (1996) Short dialyzed children respond less to growth hormone than patients prior to dialysis. German Study Group for Growth Hormone Treatment in Chronic Renal Failure. Pediatr Nephrol 10:294–298PubMedCrossRef
56.
Fine RN, Brown DF, Kuntze J, Wooster P, Kohaut EE (1996) Growth after discontinuation of recombinant human growth hormone therapy in children with chronic renal insufficiency. The Genentech Cooperative Study Group. J Pediatr 129:883–891PubMedCrossRef
57.
Fine RN, Yadin O, Moulton L, Nelson PA, Boechat MI, Lippe BM (1994) Five years experience with recombinant human growth hormone treatment of children with chronic renal failure. J Pediatr Endocrinol 7:1–12PubMedCrossRef
58.
Wollmann HA, Schonau E, Blum WF, Meyer F, Kruse K, Ranke MB (1995) Dose-dependent responses in insulin-like growth factors, insulin-like growth factor-binding protein-3 and parameters of bone metabolism to growth hormone therapy in young adults with growth hormone deficiency. Horm Res 43:249–256PubMedCrossRef
59.
Van Dyck M, Gyssels A, Proesmans W, Nijs J, Eeckels R (2001) Growth hormone treatment enhances bone mineralisation in children with chronic renal failure. Eur J Pediatr 160:359–363PubMedCrossRef
60.
Hull KL, Harvey S (2003) Growth hormone therapy and quality of life: possibilities, pitfalls and mechanisms. J Endocrinol 179:311–333PubMedCrossRef
61.
Lilien MR, Schroder CH, Levtchenko EN, Koomans HA (2004) Growth hormone therapy influences endothelial function in children with renal failure. Pediatr Nephrol 19:785–789PubMedCrossRef
62.
Lanes R, Gunczler P, Lopez E, Esaa S, Villaroel O, Revel-Chion R (2001) Cardiac mass and function, carotid artery intima–media thickness, and lipoprotein levels in growth hormone-deficient adolescents. J Clin Endocrinol Metab 86:1061–1065PubMedCrossRef
63.
Szczepaniska KJ, Tolwinska J, Urban M, Gardziejczyk M, Glowinska B (2004) Cardiac mass and function, carotid artery intima media thickness, homocysteine and lipoprotein levels in children and adolescents with growth hormone deficiency. J Pediatr Endocrinol Metab 17:1405–1413
64.
Salerno M, Esposito V, Spinelli L, Di Somma C, Farina V, Muzzica S, de Horatio LT, Lombardi G, Colao A (2004) Left ventricular mass and function in children with GH deficiency before and during 12 months GH replacement therapy. Clin Endocrinol (Oxf) 60:630–636CrossRef
65.
Fine RN, Ho M, Tejani A, Blethen S (2003) Adverse events with rhGH treatment of patients with chronic renal insufficiency and end-stage renal disease. J Pediatr 142:539–545PubMedCrossRef
66.
Mentser M, Breen TJ, Sullivan EK, Fine RN (1997) Growth-hormone treatment of renal transplant recipients: the National Cooperative Growth Study experience—a report of the National Cooperative Growth Study and the North American Pediatric Renal Transplant Cooperative Study. J Pediatr 131:S20–S24PubMedCrossRef
67.
Haffner D, Nissel R, Wuhl E, Schaefer F, Bettendorf M, Tonshoff B, Mehls O (1998) Metabolic effects of long-term growth hormone treatment in prepubertal children with chronic renal failure and after kidney transplantation. Pediatr Res 43:209–215CrossRefPubMed
68.
Saenger P, Attie KM, DiMartino-Nardi J, Fine RN (1996) Carbohydrate metabolism in children receiving growth hormone for 5 years. Chronic renal insufficiency compared with growth hormone deficiency, Turner syndrome, and idiopathic short stature. Genentech Collaborative Group. Pediatr Nephrol 10:261–263PubMedCrossRef
69.
Hertel NT, Holmberg C, Ronnholm KA, Jacobsen BB, Olgaard K, Meeuwisse GW, Rix M, Pedersen FB (2002) Recombinant human growth hormone treatment, using two dose regimens in children with chronic renal failure—a report on linear growth and adverse effects. J Pediatr Endocrinol Metab 15:577–588PubMedCrossRef
70.
Boechat MI, Winters WD, Hogg RJ, Fine RN, Watkins SL (2001) Avascular necrosis of the femoral head in children with chronic renal disease. Radiology 218:411–413PubMedCrossRef
71.
Hokken-Koelega AC, Stijnen T, de Muinck Keizer-Schrama SM, Wit JM, Wolff ED, de Jong MC, Donckerwolcke RA, Abbad NC, Bot A, Blum WF (1991) Placebo-controlled, double-blind, cross-over trial of growth hormone treatment in prepubertal children with chronic renal failure. Lancet 338:585–590PubMedCrossRef
72.
Hokken-Koelega AC, Stijnen T, de Jong MC, Donckerwolcke RA, de Muinck Keizer-Schrama SM, Blum WF, Drop SL (1994) Double blind trial comparing the effects of two doses of growth hormone in prepubertal patients with chronic renal insufficiency. J Clin Endocrinol Metab 79:1185–1190PubMed
73.
Hokken-Koelega AC, Stijnen T, de Jong RC, Donckerwolcke RA, Groothoff JW, Wolff ED, Blum WF, de Muinck Keizer-Schrama SM, Drop SL (1996) A placebo-controlled, double-blind trial of growth hormone treatment in prepubertal children after renal transplant. Kidney Int Suppl 53:S128–S134PubMed
74.
Genentech (2005) Nutropin AQ [somatropin (rDNA origin) injection]. Prescribing information
75.
Mauras N, Attie KM, Reiter EO, Saenger P, Baptista J (2000) High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech Inc Cooperative Study Group. J Clin Endocrinol Metab 85:3653–3660PubMed
76.
Mericq MV, Eggers M, Avila A, Cutler GB Jr, Cassorla F (2000) Near final height in pubertal growth hormone (GH)-deficient patients treated with GH alone or in combination with luteinizing hormone-releasing hormone analog: results of a prospective, randomized trial. J Clin Endocrinol Metab 85:569–573PubMed
77.
Saggese G, Ranke MB, Saenger P, Rosenfeld RG, Tanaka T, Chaussain JL, Savage MO (1998) Diagnosis and treatment of growth hormone deficiency in children and adolescents: towards a consensus. Ten years after the Availability of Recombinant Human Growth Hormone Workshop held in Pisa, Italy, 27–28 March 1998. Horm Res 50:320–340PubMedCrossRef
78.
Bryant J, Cave C, Mihaylova B, Chase D, McIntyre L, Gerard K, Milne R (2002) Clinical effectiveness and cost-effectiveness of growth hormone in children: a systematic review and economic evaluation. Health Technol Assess 6:1–168PubMedCrossRef
79.
Gharib H, Cook DM, Saenger PH, Bengtsson BA, Feld S, Nippoldt TB, Rodbard HW, Seibel JA, Vance ML, Zimmermann D, Palumbo PJ, Bergman DA, Garber JR, Hamilton CR Jr, Petak SM, Rettinger HI, Service FJ, Shankar TP, Stoffer SS, Tourletot JB, American Association of Clinical Endocrinologists Growth Hormone Task Force (2003) American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in adults and children—2003 update. Endocr Pract 9:64–76PubMedCrossRef
80.
National Kidney Foundation (NKF) (2003) National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42(Suppl 3):S1–S201
Metadaten
Titel
Assessment and treatment of short stature in pediatric patients with chronic kidney disease: a consensus statement
verfasst von
John D. Mahan
Bradley A. Warady
Consensus Committee
Publikationsdatum
01.07.2006
Verlag
Springer Berlin Heidelberg
Erschienen in
Pediatric Nephrology / Ausgabe 7/2006
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-006-0020-y

Weitere Artikel der Ausgabe 7/2006

Pediatric Nephrology 7/2006 Zur Ausgabe

Original Article

Urinary aquaporin-2 excretion during early human development

Original Article

Urinary neutrophil gelatinase-associated lipocalcin in D+HUS: a novel marker of renal injury

Original Article

Cyclosporin A stimulates apical Na+/H+ exchange in LLC-PK1/PKE20 proximal tubular cells

Original Article

Profiling proteinuria in pediatric patients

Brief Report

Steroid sparing effect of a herbal preparation in steroid-dependent nephrotic syndrome

Editorial Commentary

Unilateral renal ischemia causing the hyponatremic hypertensive syndrome in children—more common than we think?

Neu im Fachgebiet Pädiatrie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

16.05.2024 Arterielle Hypertonie in der Pädiatrie Nachrichten

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise